Columbus Venture Partners
VC Fund
Madrid, Spain
Columbus Venture Partners is a VC fund in Madrid focused on Biotechnology and Health Care. Columbus Venture Partners is Spanish independent venture capital. It focuses on investing in early-stage opportunities in the life science industry. The firm is a team of investment professionals with a scientific, medical, and business development background combined with experience in building and investing in companies to accelerate theircommercialization.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 57%
- Fund size:
- $127M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Columbus Venture Partners invests in
Stages Columbus Venture Partners invests in
Countries Columbus Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $1.7M–$20M
- Series B
- $28M–$87M
- Venture - Series Unknown
- $16M–$80M
Investment Focus
Industry
- Biotechnology 16 (57%)
- Health Care 8 (29%)
- Medical 4 (14%)
- Biopharma 3 (11%)
- Life Science 3 (11%)
Stage
- Venture - Series Unknown 5 (18%)
- Series B 4 (14%)
- Seed 3 (11%)
- Series A 3 (11%)
- Series C 3 (11%)
Country
- Spain 10 (36%)
- United States 3 (11%)
- United Kingdom 2 (7%)
- France 1 (4%)
- Israel 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Damià Tormo
General Partner
|
General Partner | Total investments: 9 | Find email | |
Eva Rodrigo
Chief Financial Officer & Financial Director
|
Chief Financial Officer & Financial Director | Total investments: 0 | Find email | |
Javier Garcia
Co-Founder & General Partner
|
Co-Founder & General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ona Therapeutics
|
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M / Series B / Jun 04, 2026 | |
Visium
|
Visium is a consulting company specialized in artificial intelligence, machine learning, and consulting. It delivers value to companies at every level of AI development, whether they are just entering the field or have a solid data science department. The company was founded in 2018 and headquartered in Zurich, Switzerland. | May 20, 2026 | |
Sermes
|
Sermes offers data management, monitoring, regulatory documentation, advice, consulting, information technology, and start-up services. | Private Equity / Feb 26, 2026 | |
|
Accipiter Biosciences
|
Accipiter Biosciences is a biotechnology company. | $12.7M / Seed / Nov 06, 2025 | |
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | |
Integra Therapeutics
|
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $3.2M / Seed / Sep 17, 2025 | |
|
Integra Therapeutics
|
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M / Seed / Sep 08, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
Lutris Pharma
|
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects.Lutris Pharma wasestablished in 2015 and is based in Tel Aviv-yafo, Israel. | $30M / Venture - Series Unknown / Jan 28, 2025 | |
Tolerance Bio
|
Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus. | $20.2M / Seed / Oct 15, 2024 | |
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Columbus Venture Partners invest in?
Columbus Venture Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 28 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Columbus Venture Partners's check size?
Columbus Venture Partners typically joins rounds of $1.7M–$20M at Seed, $28M–$87M at Series B and $16M–$80M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Columbus Venture Partners participates in.
How do I contact Columbus Venture Partners?
Public channels for Columbus Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Columbus Venture Partners?
The team at Columbus Venture Partners includes Damià Tormo (General Partner), Eva Rodrigo (Chief Financial Officer & Financial Director) and Javier Garcia (Co-Founder & General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
